clinical study of docetaxel, prednisone and bevacizunab in the treatment of hormone refractory prostate cancer

Abstract

Objective: To observe the clinical therapeutic effect of docetaxel, prednisone and bevacizunab in the treatment of hormone refractory prostate cancer. Methods: A total of 100 patients with hormone refractory prostate cancer were selected and randomly divided into 2 groups: chemotherapy group and combined group, 50 cases, respectively. Patients in chemotherapy group were given oral administration of hexadecadrol, 8 mg/d, intravenous drip of docetaxel, 40 mg/m2, orally taking of prednisone, 5 mg/d. Patients in combined group was added with bevacizumab, 5 mg/kg (which was diluted to 100 mL of chloride sodium injection) based on regimen of chemotherapy group. All patients were followed up every month after the end of treatment for recording reoccurrence, metastasis and deaths. Additionally, serum prostate-specific antigen (PSA), free prostate-specific antigen (fPSA)/total prostate-specific antigen (tPSA) before and after chemotherapy, prostate volume, maximum flow rate, the quality of life (QOL) were measured and evaluated. The progression-free survival (PFS) and the overall survival (OS) were analyzed by Kaplan-Meier method. Results: After treatment, the level of PSA in combined group was lower than that in chemotherapy group (P<0.01) while fPSA/tPSA in combined group was higher than that in chemotherapy group after treatment (P<0.01). The prostate volume of two groups decreased, the maximum flow rate and QOL score of two groups increased, but with no difference between two groups (P>0.05). The median PFS and OS in combined group were 13 months and 20 months, respectively, higher than those in chemotherapy group (10 months and 17 months) (P<0.01). The occurrence rate of adverse reactions was 66.00% in combined group and 56.00% in chemotherapy group, but with no significance between them (P>0.05). Conclusion: Docetaxel combined with Bevacizunab can prolong the survival time of patients with hormone refractory prostate cancer, but its therapeutic effect still needs to be further verified. Additionally, with the in-depth of studies on hormone refractory prostate cancer in translational medicine, immunotherapy, targeted therapy, individualized treatment and multidrug therapy will surely become the research hotspot for hormone refractory prostate cancer.